Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
US7951405B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2005 |
| Grant date | May 31, 2011 |
| Priority date | — |
| Expiry date | Feb 8, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K51/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.